IVF vs INMD vs NTRA vs AEYE vs EXAS

For growth investors, INVO Fertility, Inc.

(IVF) is the stronger pick with 116. 3% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, InMode Ltd.

is actually cheaper at 10. 3x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +114. 4%, compared to -100. 0% for INVO Fertility, Inc. (IVF). Over 10 years, the gap is even starker: NTRA returned +1835% versus IVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 4047% more volatile than EXAS relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INVO Fertility, Inc.

(IVF) is pulling ahead at 116. 3% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -139. 3% for INVO Fertility, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -124. 4% for IVF. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InMode Ltd.

(INMD) trades at 10. 3x forward P/E versus 582. 8x for Exact Sciences Corporation — 572. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTRA: 36. 8% to $265. 63.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IVF (Healthcare) and INMD (Healthcare) and NTRA (Healthcare) and AEYE (Technology) and EXAS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IVF is a small-cap high-growth stock; INMD is a small-cap deep-value stock; NTRA is a mid-cap high-growth stock; AEYE is a small-cap quality compounder stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.